News Feature | Published:

Approval on a knife edge

Nature Biotechnology volume 30, pages 2629 (2012) | Download Citation

In spite of its modest performance in clinical trials, Benlysta may offer effective relief against lupus. But physicians are still working to identify the right patients. Michael Eisenstein reports.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    & Nat. Biotechnol. 30, 69–77 (2012).

  2. 2.

    et al. Arthritis Rheum. 58, 2453–2459 (2008).

  3. 3.

    Anonymous. Guidance for Industry: Systemic Lupus Erythematosus—Developing Medical Products for Treatment (FDA, 2010). <>

  4. 4.

    et al. Arthritis Rheum. 61, 1168–1178 (2009).

  5. 5.

    et al. Lancet 377, 721–731 (2011).

  6. 6.

    et al. Arthritis Rheum. 62, S606 (2010).

  7. 7.

    & Clin. Pharmacol. Ther. 83, 167–171 (2008).

Download references

Author information

Affiliations

  1. Philadelphia

    • Michael Eisenstein

Authors

  1. Search for Michael Eisenstein in:

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt.2084

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing